FIGURE 4.

Carfilzomib induces bone marrow (BM) CD138⁺ cell death. A, Reduction in live BM CD138⁺ cells as a function of total BM nucleated cells after 1 cycle of carfilzomib therapy. B, BM CD138⁺ cells, unexposed to proteasome inhibitors, were incubated with control media, bortezomib, and carfilzomib. After incubation, expression of annexin-V, a marker of apoptosis, was increased in cells incubated with proteasome inhibitors compared with control media